

Composite PLLA/PP Monofilament 4DVentral[®] Promotes an Anti-Inflammatory Response In Human Macrophages *In Vitro*.





<u>Mehdi Daoudi^{1*}</u>, Cynthia CALLIGARO², Nihal Engin VRANA², Madjid Tagzirt^{3*} and Michel Caillibotte¹

*Corresponding authors: <u>m.daoudi@cousin-surgery.com</u>

¹ COUSIN SURGERY (Biotech), ALLEE des Roses, F-59117 Wervicq-Sud, France.
² SPARTHA MEDICAL, 1 Rue Eugène Boeckel, F-67000 Strasbourg, France

³ Univ. Lille, Inserm U1011- European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, F-59000 Lille, France.

BACKGOUND AND OBJECTIVES


The use of prosthetic mesh for abdominal wall repairs can significantly reduce the risk of hernia recurrence¹. However, macrophage (MØ) phenotype was reported as a predictor of constructive remodeling of abdominal connective tissue following the implantation of hernia meshs². Inflammation response characterized by an uncontrolled release of <u>pro-inflammatory M1</u> cytokines or chemokines, and tissue-degrading enzymes has been shown to be responsible for postoperative complications. In contrast, the angiogenic and tissue remodeling activities of the <u>alternative anti-inflammatory M2 pro-remodeling MØ</u> have potential use in tissue regenerative. A new type of hernia implants combines monofilaments, Polypropylene (PP) and a biobased and natural slowly bioabsorbable polymer, Poly-L-Lactic Acid (PLLA). The partially (60%) absorbable PLLA/PP and non absorbable PP meshes manufactured by COUSIN SURGERY are 4DVentral[®] and Biomesh P1[®], respectively. The contribution of PLLA in regulated inflammatory response and in enhancing abdominal repair remains unknown or unclear.

In this present study, we aimed to characterized the <u>inflammatory profiles of macrophages</u> in *vitro* in presence of composite partially absorbable PLLA/PP 4DVentral[®] compared to permanent

RESULTS

1. Composite PLLA/PP 4DVentral[®] and PP Biomesh P1[®] meshs are safe on naive THP-1 MØ

The cytotoxicity evaluation was investigated and show that both composite PLLA/PP 4DVentral[®] and nonabsorbable PP Biomesh P1[®] are nontoxic *in vitro* toward PMA-differentiated naïve THP-1 MØ in direct culture condition (**Figure 2**). Therefore, the values of cytokines produced by these cells and measured from supernatant's are systematically related to the raw values (UA) of the metabolic activity measured in each condition.




PP Biomesh P1[®] by quantify cytokine release in culture supernatants and mRNA expression levels in <u>human MØs.</u>

MATERIAL AND METHODS


Mesh. PLLA/PP 4DVentral[®] vs. PP Biomesh P1[®] meshs.

Sterilization of Mesh. ETO-sterilized.

In vitro assay Human monocytic leukemia cell line. THP-1 (10,000 cells/well in 24-well plate) were differentiated to MØ after stimulation with PMA 100 ng/ml for 3 days. The PMA-differentiated THP-1 MØ (adherent form) were then cultured with or without the meshs and pro-inflammatory cytokines (Figure 1).



Isolation of human peripheral blood monocytes and differentiation. Human blood-derived monocyte isolated by density centrifugation of heparinized blood on Ficoll-Paque were cultured with fresh complete medium (RPMI 1640) containing recombinant human IL-1 β (15 ng/ml) to obtain M1 macrophages or IL-4 (15 ng/ml) to obtain M2 macrophages.



The composite PLLA/PP 4DVentral[®] (red histograms) increases the anti-inflammatory IL-10 release after 24h of culture (**Figure 3.A**) and potentiates IL-1RA secretion at 6 days (**Figure 3.B**) in PMA-differentiated THP-1 naive MØ compared to PP Biomesh P1[®] and no mesh (red and black histograms, respectively)




Figure 3. Anti-inflammatory cytokine IL-10 (A) and IL-1RA (B) levels in the supernatant from of THP-1 naïve (M0) MØ grown after 1 days (empty boxes) and 6 days (Full boxes) of direct contact with PLLA/PP 4DVentral[®] (Red) or PP Biomesh P1[®] (Blue) vs. without mesh (Black)

3. Composite PLLA/PP 4DVentral[®] mesh increases secretion levels of the proinflammatory cytokine TNF α in naive THP-1 MØ

According to the literature about fully resorbable P4HB monofilament mesh (Phasix[®], Bard)^{3,}, we found that the composite PLLA/PP 4D Ventral[®] increases also pro-inflammatory cytokine TNF α release in naïve THP-1 MØ (**Figure 4**).



Cytotoxicity assay. Cytotoxicity of meshs was evaluated according to the ISO 10993-5 standard. The AlamarBlue[®] cell viability assay reagent was used to measure cellular metabolic activity as an indicator of cell viability, proliferation and cytotoxicity in direct or indirect (24h mesh-conditioned media) contact with Mesh. *


RNA extraction and analysis : Cells were homogenized in TRIzol[®] reagent. Total RNA was extracted using the chloroform/isopropanol/ethanol method. The gene expression were evaluated by TR-qPCR

Cytokine secretion : cytokines were quantified by Human TNF-α , IL-10 and IL-1R assay kits (Invitrogen, Carlsbad, CA).

DISCUSSION

We found that PLLA/PP 4DVentral[®] enhances polarization of human naïve MØ to an M2-like phenotype at early time (1-6 days) by increased mRNA expression levels and release of anti-inflammatory markers and cytokines. Interestingly, PLLA/PP 4DVentral[®] shifted the M1 MØ to an M2-like phenotype, mainly through induction of IL-10 secretion.

Our results shown that composite partially absorbable PLLA/PP 4DVentral[®] modulates the inflammatory profile of human MØ. The controlled transition from M1 to M2 MØ may be due to the hydrophilic properties of PLLA and/or L-lactic acid from PLLA hydrolytic degradation.






Figure 4. Cytokine TNFa levels in the supernatant of PMA-differentiated naive THP-1 MØ grown after 1 days (empty boxes) and 6 days (Full boxes) of direct contact with PLLA/PP 4DVentral[®] (Red) or PP Biomesh P1[®] (Blue) meshs vs. without mesh (Black).

4. Composite PLLA/PP 4DVentral[®] mesh drives pre-activated THP-1_{INFY/LPS} M1-like to anti-inflammatory M2-Like MØ

The composite PLLA/PP 4DVentral[®] (red histograms) inhibits the pro-inflammatory IL-6 release (Figure 5.A) and in the same way increases IL-10 secretion (Figure 5.B) compared to PP Biomesh P1[®] and no mesh (red and black histograms, respectively) in THP-1-derived MØ that were polarized with IFN- γ /LPS to the M1-type both at 24h and 6 days of culture.




Figure 5. IL-6 (A) and IL-10 (B) cytokine amounts were higher in the supernatants from of INF_Y/LPS-induced M1-Like THP-1 MØ after 1 days (empty boxes) and 6 days (Full boxes) of direct contact with PLLA/PP 4DVentral[®] (Red) compared to PP Biomesh P1[®] (Blue) vs. without mesh (Black)

5. Composite PLLA/PP 4DVentral[®] mesh potentiates the anti-inflammatory M2 profile of hMDM

CONCLUSION

It has been reported that with the transformation of MØ phenotype, the increase of IL-10 levels represents the transition of muscle regeneration from proliferation to differentiation and growth [4]. The Composite PLLA/PP partially absorbable **4DVentral**[®] could promote an anti-Inflammatory response of MØ leading to <u>Initiate the pro-regenerative process</u> of defects of the anterior abdominal wall during hernia repair by <u>targeting the Extra-Cellular Matrix (EMC)</u> <u>homeostasis</u> of abdominal connective tissue.

While waiting to confirm these results in an experimental model, we highlight the interest of using **4DVentral**[®] for treating patients with wound-healing pathologies restricting during hernia repair, with a guarantee to limit the late-stage hernia recurrence by the presence of the non-absorbable PP to abdominal reinforcement.

The composite PLLA/PP 4DVentral[®] (red histograms) potentiates the anti-inflammatory CD206 (**Figure 6.A**) and F13A (**Figure 6.B**) gene levels in IL-4-induced polarization of hMDM compared to PP Biomesh P1[®] and no mesh (red and black histograms, respectively)




Figure 6. PLLA/PP 4DVentral® (red) increases the antiinflammatory CD206 (A) and F13A (B) mRNA levels compared to PP Biomesh P1® (Blue) vs. without mesh (Black)

REFERENCES

1. Kokotovic D. et al. JAMA. 2016;316(15):1575-1582. 2. Brown B. N et al. Acta Biomater. 2012; 8(3): 978–987. 3. Molina C. P. et al. J Immunol Regen Med. 2019; (3) : 13-25. 4. Deng et al. J Immunol. 2012 Oct 1; 189 (7):3669-80.